<DOC>
	<DOC>NCT00716625</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the patients whom an investigator prescribes the first sunitinib malate(Sutent) should be registered.</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients need to be administered sunitinib malate (Sutent) in order to be enrolled in the surveillance. Patients not administered sunitinib malate (Sutent).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>